Salvage therapy is treatment given after a disease has not responded to, or has come back after, the initial treatment. The term is most commonly used in cancer care and HIV management, where first-line therapies sometimes fail to achieve lasting results. It is not a single drug or procedure but a broad category describing any second-chance treatment strategy when the standard approach falls short.
Why It’s Called “Salvage”
The name reflects the goal: salvaging a situation where the primary treatment didn’t work as hoped. This happens in two distinct scenarios. In relapsed disease, the initial treatment worked and the patient improved, but the disease returned weeks, months, or even years later. In refractory disease, the initial treatment never controlled the disease adequately in the first place. The distinction matters because relapsed patients who had a longer period of remission generally respond better to salvage therapy than those whose disease never responded or came back quickly.
Salvage Therapy in Cancer
Cancer is where the term comes up most often. When a tumor doesn’t shrink with first-line chemotherapy, or when cancer returns after an initial remission, oncologists turn to salvage regimens. These typically involve different drug combinations than what was used the first time, since the cancer has already shown it can survive the original approach.
In blood cancers like diffuse large B-cell lymphoma, salvage chemotherapy aims to shrink the disease enough to proceed with a stem cell transplant. For patients eligible for transplant, about 28% achieve a complete response with salvage chemotherapy, and roughly 34% remain progression-free at one year. For patients who aren’t candidates for transplant, outcomes are more modest, with about 23% remaining progression-free at one year. These numbers illustrate a core reality of salvage therapy: it works for a meaningful portion of patients, but success rates are lower than with first-line treatment.
In acute myeloid leukemia, there is no single salvage regimen that has proven clearly superior to others. Doctors often choose based on how long the first remission lasted and the patient’s overall health. When the first remission was long, salvage therapy has a reasonable chance of producing a second remission, which can then be followed by a stem cell transplant for a potential cure. When the first remission was short or never occurred, some patients may skip salvage chemotherapy entirely and go directly to transplant if a suitable donor is available.
Salvage Radiation for Prostate Cancer
After surgical removal of the prostate, some men see their PSA levels begin to rise, signaling that cancer cells may still be present. Salvage radiation therapy targets the area where the prostate was removed, and timing is critical. According to guidelines from the American Urological Association, salvage radiation is more effective when PSA is still very low. The current recommendation is to deliver it when PSA is at or below 0.5 ng/mL. For men at high risk of progression, doctors may offer it even earlier, at PSA levels below 0.2 ng/mL. Data from over 6,000 patients consistently shows better outcomes when salvage radiation is given sooner rather than later.
Salvage Therapy in HIV
In HIV treatment, salvage therapy refers to constructing a new drug regimen after the virus has developed resistance to previous medications. This is triggered when blood tests show the virus is no longer being suppressed, defined as HIV levels persistently at or above 200 copies per milliliter. At that point, the virus is often accumulating mutations that make it resistant to the current drugs.
Building a new salvage regimen requires resistance testing to figure out which drugs the virus is still vulnerable to. The goal is to include at least two fully active drugs, with at least one that has a high barrier to resistance, meaning the virus would need many mutations to overcome it. Newer-generation drugs in existing classes are often effective even when the virus has developed resistance to older drugs in the same family. If no high-barrier drug is available, doctors aim to combine at least three drugs that are still fully active against the patient’s specific strain.
Curative vs. Palliative Intent
Not all salvage therapy aims for a cure. In some cases, the goal shifts to controlling the disease and extending life as long as possible. The difference in outcomes can be stark. In a study of patients with recurrent non-small cell lung cancer, those who received curative-intent salvage treatment (aggressive surgery or high-dose radiation) had a median survival of 34.3 months and a five-year survival rate of about 30%. Those who received palliative salvage treatment had a median survival of just 9.8 months, with a five-year survival rate under 4%.
Whether salvage therapy is curative or palliative depends on several factors: how localized the recurrence is, the patient’s overall fitness, and what treatments were already used. Someone whose cancer returns in a single spot may be a candidate for aggressive, potentially curative salvage treatment. Someone with widespread recurrence is more likely to receive treatment aimed at symptom control and life extension.
CAR-T Cell Therapy as a Salvage Option
One of the newer salvage options for certain blood cancers is CAR-T cell therapy, where a patient’s own immune cells are reprogrammed in a lab to recognize and attack cancer. For relapsed or refractory diffuse large B-cell lymphoma, CAR-T therapy produces a one-year progression-free survival rate of about 40%, which is comparable to or slightly better than traditional salvage chemotherapy followed by stem cell transplant in the same setting. Interestingly, some newer targeted drug combinations have shown similar effectiveness to CAR-T in patients who aren’t transplant candidates, suggesting the salvage landscape is becoming more diverse.
Higher Risks Than First-Line Treatment
Salvage treatments generally carry greater risks than initial therapy. The body has already absorbed the effects of one round of treatment, and tissues may be less tolerant of further intervention. This is especially visible in prostate cancer, where salvage surgery after prior radiation carries higher rates of complications than primary surgery. Robotic-assisted salvage prostatectomy still results in erectile dysfunction in 87% to 100% of cases and intermittent urinary incontinence in 27% to 77%. Salvage cryotherapy (freezing the tissue) carries a 10% to 30% incontinence rate and near-universal erectile dysfunction.
These elevated risks exist because salvage treatments are working on tissue that has already been stressed by prior therapy. Radiation-treated tissue is more fragile, chemotherapy-exposed bone marrow is less resilient, and organs that were near their tolerance limits the first time have little margin left. This is why the decision to pursue salvage therapy always involves weighing the realistic chance of benefit against the likelihood of significant side effects.